Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Angiotech, Cook deal

The companies amended a 1997 deal under which Cook received a co-exclusive, worldwide license from ANP to use paclitaxel in stents

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE